Terms: = Breast cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809
2730 results:
1. pDNA-tachyplesin treatment stimulates the immune system and increases the probability of apoptosis in MC4-L2 tumor cells.
Mahmoudi-Filabadi F; Doosti A
Amino Acids; 2024 May; 56(1):34. PubMed ID: 38691208
[TBL] [Abstract] [Full Text] [Related]
2. Augmented ERO1α upon mtorC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11.
Wang Z; Zong H; Liu W; Lin W; Sun A; Ding Z; Chen X; Wan X; Liu Y; Hu Z; Zhang H; Li H; Liu Y; Li D; Zhang S; Zha X
J Exp Clin Cancer Res; 2024 Apr; 43(1):112. PubMed ID: 38610018
[TBL] [Abstract] [Full Text] [Related]
3. ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway.
Zhou X; Zhao J; Yan T; Ye D; Wang Y; Zhou B; Liu D; Wang X; Zheng W; Zheng B; Qian F; Li Y; Li D; Fang L
Cell Death Dis; 2024 Apr; 15(4):260. PubMed ID: 38609357
[TBL] [Abstract] [Full Text] [Related]
4. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
5. The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features.
Salaün H; Djerroudi L; Haik L; Schnitzler A; Bataillon G; Deniziaut G; Bièche I; Vincent-Salomon A; Debled M; Cottu P
J Pathol Clin Res; 2024 May; 10(3):e12372. PubMed ID: 38563252
[TBL] [Abstract] [Full Text] [Related]
6. The PI3K/AKT/mtor signaling pathway in breast cancer: Review of clinical trials and latest advances.
Khorasani ABS; Hafezi N; Sanaei MJ; Jafari-Raddani F; Pourbagheri-Sigaroodi A; Bashash D
Cell Biochem Funct; 2024 Apr; 42(3):e3998. PubMed ID: 38561964
[TBL] [Abstract] [Full Text] [Related]
7. Optimal targeting of PI3K-AKT and mtor in advanced oestrogen receptor-positive breast cancer.
Browne IM; André F; Chandarlapaty S; Carey LA; Turner NC
Lancet Oncol; 2024 Apr; 25(4):e139-e151. PubMed ID: 38547898
[TBL] [Abstract] [Full Text] [Related]
8. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM; Han HS; Rugo HS; Stringer-Reasor EM; Specht JM; Dees EC; Kabos P; Suzuki S; Mutka SC; Sullivan BF; Gorbatchevsky I; Wesolowski R
Lancet Oncol; 2024 Apr; 25(4):474-487. PubMed ID: 38547892
[TBL] [Abstract] [Full Text] [Related]
9. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic breast cancer Harboring Altered PI3K/AKT/mtor.
Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
[TBL] [Abstract] [Full Text] [Related]
10. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/Akt/mtor pathway.
Guo M; Liu M; Li W; Wang C; Zhang L; Zhang H
J Cancer Res Clin Oncol; 2024 Mar; 150(3):155. PubMed ID: 38526702
[TBL] [Abstract] [Full Text] [Related]
11. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mtor signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
12. Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling.
De Marchi T; Lai CF; Simmons GM; Goldsbrough I; Harrod A; Lam T; Buluwela L; Kjellström S; Brueffer C; Saal LH; Malmström J; Ali S; Niméus E
Sci Rep; 2024 Mar; 14(1):6873. PubMed ID: 38519482
[TBL] [Abstract] [Full Text] [Related]
13. Scutellarin, a flavonoid compound from Scutellaria barbata, suppresses growth of breast cancer stem cells in vitro and in tumor-bearing mice.
Ma H; Yue GG; Lee JK; Gao S; Yuen KK; Cheng W; Li X; Lau CB
Phytomedicine; 2024 Jun; 128():155418. PubMed ID: 38518647
[TBL] [Abstract] [Full Text] [Related]
14. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mtor signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
15. Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
Gómez Tejeda Zañudo J; Barroso-Sousa R; Jain E; Jin Q; Li T; Buendia-Buendia JE; Pereslete A; Abravanel DL; Ferreira AR; Wrabel E; Helvie K; Hughes ME; Partridge AH; Overmoyer B; Lin NU; Tayob N; Tolaney SM; Wagle N
Nat Commun; 2024 Mar; 15(1):2446. PubMed ID: 38503755
[TBL] [Abstract] [Full Text] [Related]
16. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy.
Mohan CD; Shanmugam MK; Gowda SGS; Chinnathambi A; Rangappa KS; Sethi G
Phytomedicine; 2024 Jun; 128():155379. PubMed ID: 38503157
[TBL] [Abstract] [Full Text] [Related]
17. Elevated aerobic glycolysis driven by p62-mtor axis promotes arsenic-induced oncogenic phenotypes in human mammary epithelial cells.
Li Y; Liu J; Yao D; Guo Z; Jiang X; Zhang C; Qu L; Liu Y; Hu Y; Gao L; Wang Y; Xu Y
Arch Toxicol; 2024 May; 98(5):1369-1381. PubMed ID: 38485781
[TBL] [Abstract] [Full Text] [Related]
18. Everolimus decreases [U-
Ariaans G; Tiersma JF; Evers B; Gerding A; Waaijer SJH; Koster RA; Touw DJ; Bakker BM; Reijngoud DJ; de Jong S; Jalving M
Biomed Pharmacother; 2024 Apr; 173():116362. PubMed ID: 38432130
[TBL] [Abstract] [Full Text] [Related]
19. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
[TBL] [Abstract] [Full Text] [Related]
20. Hijacking 5-Fluorouracil Chemoresistance in Triple Negative breast cancer via microRNAs-Loaded Chitosan Nanoparticles.
Fahmy SA; Mahdy NK; Mohamed AH; Mokhtar FA; Youness RA
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396746
[TBL] [Abstract] [Full Text] [Related]
[Next]
